GHENT, BELGIUM--(Marketwire - July 05, 2010) -
GHENT, Belgium, 5 July 2010 - Ablynx [Euronext Brussels: ABLX], announced
that it has been awarded a grant worth EUR1.1 million by the Flemish
Innovation by Science and Technology (IWT) and a second grant worth EUR0.4
from the Portuguese government, as part of a consortium.
The IWT grant allows Ablynx to accelerate its pre-clinical
programme, ALX-0171, for the treatment of respiratory syncytial virus
infections. ALX-0171 binds to RSV and neutralises the virus. The Nanobody
be administered via the lungs and based on in vivo data, it has the
be effective both in the prevention of infection as well as in treatment
infection has occurred.
ALX-0171 is Ablynx's first Nanobody pre-clinical development candidate
delivered through a route other than injection. Like many Nanobodies,
is very stable, making it suitable for inhalation. It can also be
at relatively low cost in microbial systems.
The grant from the Portuguese government will allow Ablynx and
collaborators, to explore routes of delivery for Nanobodies into the
nervous system (CNS) and to develop Nanobodies against therapeutically
Edwin Moses, CEO and Chairman of Ablynx, said: "We are delighted with
continued support of Ablynx's Nanobody platform as well as with this
grant from the Portuguese government which will allow us to further
develop Nanobody-based therapies for CNS diseases where the unmet medical
is very high. Today, we have over 25 therapeutic programmes in our
with four Nanobody products in clinical development."
Complete version of the press release:
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Ablynx via Thomson Reuters ONE